In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA(2)DS(2)-VASc >4. Romiti GF, Talerico G. Ann Intern Med 2024;177:JC125.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Romiti GF, Talerico G. In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA(2)DS(2)-VASc >4. Ann Intern Med 2024;177:JC125.
PMID: 39496171